These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 31196374)
1. [A Case of Pseudoprogression During Atezolizumab Therapy in Lung Adenocarcinoma]. Wang X; Zhao Y; Chen Z Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):389-394. PubMed ID: 31196374 [TBL] [Abstract][Full Text] [Related]
2. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? Zhang Y; Zhou H; Zhang L J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312 [TBL] [Abstract][Full Text] [Related]
3. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. Hoffner B; Leighl NB; Davies M Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962 [TBL] [Abstract][Full Text] [Related]
4. Durvalumab for the treatment of non-small cell lung cancer. Murakami S Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989 [No Abstract] [Full Text] [Related]
6. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
8. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. Leventakos K; Mansfield AS BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930 [TBL] [Abstract][Full Text] [Related]
9. Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies. Fujita K; Uchida N; Yamamoto Y; Kanai O; Okamura M; Nakatani K; Sawai S; Mio T Anticancer Res; 2019 Jul; 39(7):3917-3921. PubMed ID: 31262921 [TBL] [Abstract][Full Text] [Related]
10. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Seike M; Gemma A; Nishio M BMC Cancer; 2020 Mar; 20(1):207. PubMed ID: 32164651 [TBL] [Abstract][Full Text] [Related]
11. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. Spigel DR; Chaft JE; Gettinger S; Chao BH; Dirix L; Schmid P; Chow LQM; Hicks RJ; Leon L; Fredrickson J; Kowanetz M; Sandler A; Funke R; Rizvi NA J Thorac Oncol; 2018 Nov; 13(11):1733-1742. PubMed ID: 29775807 [TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
13. A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer. Yin J; Dong J; Gao W; Wang Y Medicine (Baltimore); 2018 Nov; 97(44):e13112. PubMed ID: 30383701 [TBL] [Abstract][Full Text] [Related]
14. Prospects and progress of atezolizumab in non-small cell lung cancer. Vansteenkiste J; Wauters E; Park K; Rittmeyer A; Sandler A; Spira A Expert Opin Biol Ther; 2017 Jun; 17(6):781-789. PubMed ID: 28335643 [TBL] [Abstract][Full Text] [Related]
15. Atezolizumab for the treatment of non-small cell lung cancer. Santini FC; Rudin CM Expert Rev Clin Pharmacol; 2017 Sep; 10(9):935-945. PubMed ID: 28714780 [TBL] [Abstract][Full Text] [Related]
16. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR; Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383 [TBL] [Abstract][Full Text] [Related]
17. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Liu SV; Camidge DR; Gettinger SN; Giaccone G; Heist RS; Hodi FS; Ready NE; Zhang W; Wallin J; Funke R; Waterkamp D; Foster P; Iizuka K; Powderly J Eur J Cancer; 2018 Sep; 101():114-122. PubMed ID: 30053670 [TBL] [Abstract][Full Text] [Related]
18. Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer. Blair HA Target Oncol; 2018 Jun; 13(3):399-407. PubMed ID: 29785577 [TBL] [Abstract][Full Text] [Related]
19. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers. Krishnamurthy A; Jimeno A Drugs Today (Barc); 2017 Apr; 53(4):217-237. PubMed ID: 28492290 [TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]